These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572 [TBL] [Abstract][Full Text] [Related]
4. [Human cytotoxic T lymphocyte responses specific to the DNA vaccine of Wilms' tumor gene product]. Zhang B; Wang Z Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jul; 29(7):1348-50. PubMed ID: 19620050 [TBL] [Abstract][Full Text] [Related]
6. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Gaiger A; Reese V; Disis ML; Cheever MA Blood; 2000 Aug; 96(4):1480-9. PubMed ID: 10942395 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Eslami NS; Shokrgozar MA; Mousavi A; Azadmanesh K; Nomani A; Apostolopoulos V; Day S; Amanzadeh A; Alimohammadian MH Mol Immunol; 2012 Jul; 51(3-4):325-31. PubMed ID: 22525006 [TBL] [Abstract][Full Text] [Related]
8. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Ohminami H; Yasukawa M; Fujita S Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714 [TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319 [TBL] [Abstract][Full Text] [Related]
10. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188 [TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor gene WT1: its oncogenic function and clinical application. Sugiyama H Int J Hematol; 2001 Feb; 73(2):177-87. PubMed ID: 11372729 [TBL] [Abstract][Full Text] [Related]
12. WT1 as a novel target antigen for cancer immunotherapy. Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920 [TBL] [Abstract][Full Text] [Related]
13. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro]. Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569 [TBL] [Abstract][Full Text] [Related]
14. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359 [TBL] [Abstract][Full Text] [Related]
15. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. Schirmbeck R; Böhm W; Reimann J J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655 [TBL] [Abstract][Full Text] [Related]
16. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755 [TBL] [Abstract][Full Text] [Related]
17. WT1 peptide vaccine for the treatment of cancer. Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632 [TBL] [Abstract][Full Text] [Related]